A new treatment for choroidal, retinal and corneal neovascularization with targeting to alfa-9 integrin ligand
Project/Area Number |
22791680
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Ophthalmology
|
Research Institution | Wakayama Medical University |
Principal Investigator |
FUJITA Norihito 和歌山県立医科大学, 医学部, 博士研究員 (10453177)
|
Project Period (FY) |
2010-04-01 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
Keywords | α9インテグリン / 血管新生 / 脈絡膜 / 角膜 / 網膜 / α9インテグリン |
Research Abstract |
This study provide evidence that endogenous alfa-9 integrin ligand including osteopontin or tenascin-C at physiological levels inhibits induced angiogenesis in laser-induced choroidal neovascularization (CNV) in vivo. Mechanism of action might include the effects of alfa-9 integrin ligand on vascular endothelial cells. Blocking alfa-9 integrin ligand activity might be a potential strategy for the prevention or treatment of CNV in an age-related macular degeneration (AMD) patient. A clinical trial by using antibody is to be set up for establishment of a new AMD treatment strategy.
|
Report
(5 results)
Research Products
(17 results)